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Does treatment with donepezil
improve memory for patients 
with mild cognitive impairment?
z Evidence summary
Mild cognitive impairment is defined as
memory loss that is out of proportion to
that expected for one’s age but which does
not meet the clinical criteria for dementia.
The diagnosis of dementia requires cogni-
tive impairment plus functional impair-
ment. In mild cognitive impairment, 
function is preserved by definition. 
Several studies have shown that
patients with mild cognitive impairment
progress to Alzheimer’s disease at a higher
rate than normal elderly patients.2,3
Research has focused on therapies that
have shown a positive benefit for patients
with Alzheimer’s disease.4,5 Cholinesterase
inhibitors, including donepezil, have
shown some benefit in cognition and func-
tion for patients with mild to moderate
Alzheimer’s disease. Two randomized con-
trolled trials (RCTs) address the effect of
donepezil on mild cognitive impairment.
The National Institute of Aging con-
ducted a double-blind RCT multicenter
study, which enrolled a total of 769 sub-
jects with mild cognitive impairment. The
Donepezil (Aricept) has potential benefit 
in delaying risk of progression to
Alzheimer’s disease in the first year of 
treatment, but this benefit is not seen 
at 3 years. Donepezil does not improve
memory for patients with mild 
cognitive impairment (strength of 
recommendation: B).
E V I D E N C E - B A S E D A N S W E R
Donepezil’s cost, limited proven benefit,
side effects argue against it 
as standard of care
The downward spiral of a patient with
Alzheimer’s disease is heartbreaking, so
any possibility of slowing this process is
welcome. Many physicians, when 
challenged with the desire to assist the
patient with mild cognitive impairment and
their family, review the data showing that
donepezil slows progression in Alzheimer’s
disease, as well as briefly from mild 
cognitive impairment to Alzheimer’s disease.
They discuss with the family the imprecise
nature of diagnosis,1 risks vs benefits of
therapy, and start an 8-week trial of therapy.
If the family notes improvement (or stabiliza-
tion), treatment can be continued. However,
the cost of the medication, the limited
proven benefit, and the side-effect profile
argue against any clear standard of care.
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primary outcome was the development of
possible or probable Alzheimer’s disease,
and secondary outcomes included cogni-
tion and function. Subjects were randomly
assigned to receive 2000 IU of vitamin E,
10 mg of donepezil, or placebo daily for 
3 years. Of the total, 214 (28%) of the
study subjects progressed to dementia,
with 212 classified as possible or probable
Alzheimer’s disease. Analysis of the treat-
ment effects at 6-month intervals showed a
decreased probability of progression to
Alzheimer’s disease in the donepezil group
during the first 12 months of the study,
compared with placebo (14.7% vs 6.3%;
P=.04; number needed to treat [NNT]=
12), but this change did not persist to 3
years. 
Several of the psychometric tests
showed statistically significant differences
(scores for Mini-Mental State Examination
[MMSE], Clinical Dementia Rating [CDR]
sum of boxes, Global Deterioration Scale,
and modified Alzheimer’s disease Assess-
ment Scale-cognitive subscale [ADAS-cog])
early in the study, but the effect was only
detected in the first 12 months of the
study.6,7 The donepezil group had signifi-
cantly higher rates diarrhea, muscle
cramps, insomnia, nausea, and abnormal
dreams (P<.01). There was no difference in
discontinuation rates between the groups.7
The second study was a 24-week mul-
ticenter RCT, which included 270 patients
with amnestic mild cognitive impairment.
Patients were randomized to receive place-
bo or donepezil (5 mg/d for 42 days, 
followed by 10 mg/d). The primary end-
points were changes on the New York
University Paragraph Delayed Recall test
and the Alzheimer’s disease Cooperative
Study Clinician’s Global Impression of
Change for Mild Cognitive Impairment
(ADCS CGIC-MCI). No significant differ-
ences were found in the primary endpoints
at 24 weeks—32.6% in the donepezil
group vs 24.3 % in the placebo group
showed minimal or moderate improve-
ment, and 51.7% in the donepezil group vs
60.4% in the placebo group showed no
change. Secondary endpoints included the
modified ADAS-cog, the Patient Global
Assessment (PGA) and other neuropsycho-
logical tests. 
The ADAS-cog focuses on psycho-
motor speed and attention tests. Analysis
of the ADAS-cog favored the donepezil
group, with 22.3% showing a ≥7-point
score vs 12.1% in the placebo group.
There were no significant differences on
the PGA in the intention-to-treat analysis.8
The donepezil group had a higher rate of
adverse drug reactions (P<.03) including
diarrhea, nausea, vomiting, leg cramps,
and abnormal dreams. The discontinua-
tion rate was 22% in the donepezil group
compared with 8% in the placebo group
(number needed to harm=7).8
Recommendations from others
We found no recommendations about
using cholinesterase inhibitors in mild 
cognitive impairment.
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The cost of
cholinesterase
inhibitors and their
limited benefit 
for mild cognitive
impairment argue
against any clear
standard of care
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